Effectiveness of Oral 5-HT₃ Receptor Antagonists for Emetogenic Chemotherapy

Paula J. Anastasia, RN, MN

Purpose/Objectives: To review the efficacy and safety of the oral 5-hydroxytryptamine, (5-HT₃) receptor antagonists and the use of oral and IV antiemetic therapy during and after hospital admission.

Data Sources: Articles in medical and nursing literature

Data Synthesis: Use of oral antiemetics may help patients avoid potential complications associated with IV administration and be more convenient. They also are likely to lower staff and materials costs compared to IV formulations. Oral granisetron is the only oral antiemetic approved in the United States for use with highly emetogenic chemotherapy regimens. Oral dolasetron and ondansetron are indicated for use with moderately emetogenic chemotherapy

Conclusions: Oral therapy is preferable to IV formulations for most patients. The oral 5-HT₃ receptor antagonists approved for chemotherapy-induced nausea and vomiting include dolasetron, granisetron, and ondansetron. Oral granisetron is differentiated for its safety, efficacy, and ease of use in highly and moderately emetogenic chemotherapy

Implications for Nursing Practice: Oral antiemetics are preferable to IV antiemetics because of decreased total costs and greater convenience for patients who are able to ingest oral medication.

As cytotoxic chemotherapy has evolved, so have the agents used to treat or prevent chemotherapy-induced side effects such as nausea and vomiting. The development of 5-hydroxytryptamine, (5-HT₃) receptor antagonists has greatly improved the control of acute vomiting (Ettinger, 1995; Perez, 1995). Three 5-HT₃ antagonists are approved for use in the United States: granisetron (Kytril, SmithKline Beecham Pharmaceuticals, Philadelphia, PA), ondansetron (Zofran, Glaxo Wellcome Inc., Research Triangle Park, NC), and, most recently, dolasetron mesylate (Anzemet, Hoechst Marion Roussel, Inc., Kansas City, MO).

The three agents marketed in the United States are available in injectable and oral formulations. Efficacy of IV formulations for the three agents is similar according to several comparative studies (Aldhuy et al., 1994; Gebbia et al., 1994; Hesketh et al., 1996; Martoni, Angelelli, Guaraldi, Strocchi, & Pannuti, 1994; Navari et al., 1995; Noble et al., 1994; Ruff et al., 1994), but differences have been noted among the oral formulations. Oral ondansetron (recommended dosage 8 mg bid) and dolasetron (recommended dosage 100 mg qd) are approved in the United States for prevention of emesis associated with moderately emetogenic chemotherapy, such as carboplatin- and cyclophosphamide-based regimens. Only oral granisetron (2 mg qd) is indicated for preventing nausea and vomiting associated with highly and moderately emetogenic chemotherapy, including high-dose cisplatin (SmithKline Beecham Pharmaceuticals, 1997a).

Release of serotonin (5-HT) from enterochromaffin cells in the small intestinal mucosa contributes to acute nausea and vomiting associated with chemotherapy (Cubeddu, Hoffmann, Fuenmayor, & Finn, 1990). Serotonin activates receptors on vagal afferent fibers in the intestinal mucosa, which relays sensory information to discrete brain areas involved in nausea and vomiting (Cubeddu et al.; Ettinger, 1995). Oral 5-HT₃ receptor antagonists act by blocking the serotonin receptors in the gastrointestinal tract.

Key Points...

- The 5-HT₃ receptor antagonists are the newest generation of antiemetic drugs.
- Three currently are approved for use in the United States, but, because of cost, their use has been restricted to patients receiving particularly emetogenic chemotherapy.
- All three drugs are effective against mild to moderately severe nausea and vomiting, but only granisetron has been approved for use in patients receiving highly emetogenic drugs.*
- Use of all these drugs mandate careful patient assessment, patient education, and choice of the most appropriate route of administration to achieve the desired results in the most cost-effective manner.

Paula J. Anastasia, RN, MN, is a GYN oncology clinical nurse specialist at Cedars-Sinai Medical Center in Los Angeles, CA. When this article was written, she was an oncology nurse educator at SmithKline Beecham Pharmaceuticals in Plainsboro, NJ. (Submitted July 1998. Accepted for publication September 10, 1999.) ( Mention of specific products and opinions related to these products do not indicate or imply endorsement by the Oncology Nursing Forum or the Oncology Nursing Society.)